shot-button
Maharashtra Elections 2024 Maharashtra Elections 2024
Home > News > India News > Article > COVID 19 battle far from over Harsh Vardhan tells Rajya Sabha

COVID-19 battle far from over, Harsh Vardhan tells Rajya Sabha

Updated on: 15 September,2020 02:15 PM IST  |  Mumbai
IANS |

India on Tuesday reported a spike of 83,000 new cases in the last 24 hours, taking the countrys total tally past 49-lakh mark to 49,30,237, including 9,90,061 active cases

COVID-19 battle far from over, Harsh Vardhan tells Rajya Sabha

Union Health Minister Harsh Vardhan. Pic/Twitter Harsh Vardhan

Sounding a note of caution, Union Health Minister Harsh Vardhan on Tuesday told the Rajya Sabha that the battle against Covid-19 is far from over, at a time when India's total tally has neared the five million-mark.


"I would urge all Members of Parliament that the coronavirus battle is still far from over. On one hand, when we are in an Unlock stage to revive the Indian economy, and have a balanced approach, it is important that sustained community support is ensured to control the spread of the virus and break its chain of transmission," Vardhan said in the Upper House.



India on Tuesday reported a spike of 83,000 new cases in the last 24 hours, taking the country's total tally past 49-lakh mark to 49,30,237, including 9,90,061 active cases.

"COVID-19 fatality and recovery rates stand at 1.67% and 77.65% respectively. Maximum cases and deaths have primarily been reported from Maharashtra, Andhra Pradesh, Tamil Nadu, Karnataka, Uttar Pradesh, Delhi, West Bengal, Bihar, Telangana, Odisha, Assam, Kerala, and Gujarat," the Minister said.

He said about 40 lakh persons were under surveillance. "Extensive contact tracing of all positive cases is being undertaken regularly through disease surveillance network so as to break the chain of transmission," he added.

Vardhan also spoke about the clinical management of coronavirus, pointing out that no specific antiviral drugs have proved effective so far while the symptomatic treatment for fever and cough, appropriate rehydration, and supplemental oxygen therapy remained the mainstay of treatment.

The Minister, however, said that in India, drug hydroxychloroquine has been re-purposed for mild and moderate cases. In addition, provisions for investigational therapies have also been made through the use of Remdesivir, convalescent plasma, and Tocilizumab for managing severe cases under close medical supervision.

India has been able to limit its cases and deaths to 3,320 cases per million and 55 deaths per million which is one of the lowest in the world, he added.

On Monday, Vardhan had said that lockdown helped prevent approximately 14 lakh to 29 lakh cases and 37,000 to 78,000 deaths. These four months were utilised to create additional health infrastructure, enhance human resources, and produce within Indian critical elements such as PPE kits, N95 masks and ventilators.

"A case in point is the increase in isolation beds 36.3 times and dedicating ICU beds above 24.6 times to what existed in March 2020. We are now self-sufficient and in position to even export PPEs," he had added.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK